IBD metabonomics predicts phenotype, disease course, and treatment response

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Standard

IBD metabonomics predicts phenotype, disease course, and treatment response. / Bjerrum, Jacob T.; Wang, Yulan L.; Seidelin, Jakob B.; Nielsen, Ole H.

I: EBioMedicine, Bind 71, 103551, 2021.

Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt

Harvard

Bjerrum, JT, Wang, YL, Seidelin, JB & Nielsen, OH 2021, 'IBD metabonomics predicts phenotype, disease course, and treatment response', EBioMedicine, bind 71, 103551. https://doi.org/10.1016/j.ebiom.2021.103551

APA

Bjerrum, J. T., Wang, Y. L., Seidelin, J. B., & Nielsen, O. H. (2021). IBD metabonomics predicts phenotype, disease course, and treatment response. EBioMedicine, 71, [103551]. https://doi.org/10.1016/j.ebiom.2021.103551

Vancouver

Bjerrum JT, Wang YL, Seidelin JB, Nielsen OH. IBD metabonomics predicts phenotype, disease course, and treatment response. EBioMedicine. 2021;71. 103551. https://doi.org/10.1016/j.ebiom.2021.103551

Author

Bjerrum, Jacob T. ; Wang, Yulan L. ; Seidelin, Jakob B. ; Nielsen, Ole H. / IBD metabonomics predicts phenotype, disease course, and treatment response. I: EBioMedicine. 2021 ; Bind 71.

Bibtex

@article{e9d4ed45510f4885b57665a8847bdd6b,
title = "IBD metabonomics predicts phenotype, disease course, and treatment response",
abstract = "Metabonomics in inflammatory bowel disease (IBD) characterizes the effector molecules of biological systems and thus aims to describe the molecular phenotype, generate insight into the pathology, and predict disease course and response to treatment. Nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and integrated NMR and MS platforms coupled with multivariate analyses have been applied to create such metabolic profiles. Recent advances have identified quiescent ulcerative colitis as a distinct molecular phenotype and demonstrated metabonomics as a promising clinical tool for predicting relapse and response to treatment with biologics as well as fecal microbiome transplantation, thus facilitating much needed precision medicine. However, understanding this complex research field and how it translates into clinical settings is a challenge. This review aims to describe the current workflow, analytical strategies, and associated bioinformatics, and translate current IBD metabonomic knowledge into new potential clinically applicable treatment strategies, and outline future key translational perspectives.",
keywords = "Crohn's disease, Metabolic profiling, Metabolomics, Spectrometry, Spectroscopy, Ulcerative colitis",
author = "Bjerrum, {Jacob T.} and Wang, {Yulan L.} and Seidelin, {Jakob B.} and Nielsen, {Ole H.}",
note = "Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2021",
doi = "10.1016/j.ebiom.2021.103551",
language = "English",
volume = "71",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - IBD metabonomics predicts phenotype, disease course, and treatment response

AU - Bjerrum, Jacob T.

AU - Wang, Yulan L.

AU - Seidelin, Jakob B.

AU - Nielsen, Ole H.

N1 - Publisher Copyright: © 2021 The Authors

PY - 2021

Y1 - 2021

N2 - Metabonomics in inflammatory bowel disease (IBD) characterizes the effector molecules of biological systems and thus aims to describe the molecular phenotype, generate insight into the pathology, and predict disease course and response to treatment. Nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and integrated NMR and MS platforms coupled with multivariate analyses have been applied to create such metabolic profiles. Recent advances have identified quiescent ulcerative colitis as a distinct molecular phenotype and demonstrated metabonomics as a promising clinical tool for predicting relapse and response to treatment with biologics as well as fecal microbiome transplantation, thus facilitating much needed precision medicine. However, understanding this complex research field and how it translates into clinical settings is a challenge. This review aims to describe the current workflow, analytical strategies, and associated bioinformatics, and translate current IBD metabonomic knowledge into new potential clinically applicable treatment strategies, and outline future key translational perspectives.

AB - Metabonomics in inflammatory bowel disease (IBD) characterizes the effector molecules of biological systems and thus aims to describe the molecular phenotype, generate insight into the pathology, and predict disease course and response to treatment. Nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and integrated NMR and MS platforms coupled with multivariate analyses have been applied to create such metabolic profiles. Recent advances have identified quiescent ulcerative colitis as a distinct molecular phenotype and demonstrated metabonomics as a promising clinical tool for predicting relapse and response to treatment with biologics as well as fecal microbiome transplantation, thus facilitating much needed precision medicine. However, understanding this complex research field and how it translates into clinical settings is a challenge. This review aims to describe the current workflow, analytical strategies, and associated bioinformatics, and translate current IBD metabonomic knowledge into new potential clinically applicable treatment strategies, and outline future key translational perspectives.

KW - Crohn's disease

KW - Metabolic profiling

KW - Metabolomics

KW - Spectrometry

KW - Spectroscopy

KW - Ulcerative colitis

U2 - 10.1016/j.ebiom.2021.103551

DO - 10.1016/j.ebiom.2021.103551

M3 - Review

C2 - 34419930

AN - SCOPUS:85113178565

VL - 71

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

M1 - 103551

ER -

ID: 278482986